Measurable disease by RECIST

Greater than or equal to 18 years of age

ECOG PS of 0 or 1

Radiation therapy within 2 weeks; chemotherapy within 3 weeks; non-cytotoxic investigational agents within 4 weeks of initiating study treatment

Evidence of NYHA class III or greater cardiac disease

History of MI, stroke, ventricular arrhythmia, or symptomatic conduction abnormality within 12 months

Known HIV infection or AIDS

Symptomatic CNS metastases

Pregnant or nursing women

Hypersensitivity or intolerance to erlotinib, sulfonamides, aspirin, or other NSAIDs.

History of upper GI bleeding, ulceration, or perforation

Prior history of COX-2 inhibitor therapy for the treatment of metastatic NSCLC

Previous anti-EGFR kinase therapy

APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung Cancer